Out-licencing and Partnerships

Product or program

Indication

Research Preclinical Phase 1 Phase 2 Phase 3 Registration

Tesofensine

Obesity

NS2359

Cocaine addiction

CAD-1883

Essential tremor

Spinocerebellar ataxia

GABA a5

Schizophrenia

Undisclosed

Schizophrenia

Completed

Ongoing

In planning